Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30241 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Katelyn N Swizer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Down Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan, USA.
- Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Miriam B Garcia
Zitieren
APA
Swizer, K. N., Beebe, M., & Garcia, M. B. (2023). Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30241
Vancouver
Swizer KN, Beebe M, Garcia MB. Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30241
BibTeX
@article{Swizer2023,
author = {Swizer, Katelyn N and Beebe, Morgan and Garcia, Miriam B},
title = {Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30241}
}
EUVIMED